VFF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
VFF is not a good buy right now for an impatient investor. The stock is oversold and sitting near support (possible short bounce), but momentum is still deteriorating (negative/expanding MACD) and insider selling has surged, which weakens the near-term risk/reward despite bullish options positioning and positive export-related news.
Price closed at 3.305 (-2.37% day) with the broader market slightly down. Momentum/trend: MACD histogram is negative (-0.0105) and negatively expanding, signaling downside momentum is still building. RSI(6) is 26.43 (oversold), which can set up a reflex bounce, but it is not a confirmed reversal by itself. Moving averages are converging, consistent with a choppy/indecisive tape rather than a clean uptrend. Levels: immediate support S1=3.283 then S2=3.188; a breakdown below ~3.28 increases risk of a quick drop toward ~3.19. Resistance/pivot: Pivot=3.435, then R1=3.588; bulls likely need a reclaim of ~3.44 to shift the near-term bias. Pattern-based odds suggest a modest bullish skew over 1W/1M, but current momentum signals argue for caution.
Intellectia Proprietary Trading Signals: Intellectia Proprietary Trading Signals
Export momentum and recognition: award win (BC Export Awards) and commentary highlighting international medical cannabis exports (Germany/UK/Israel) via EU-GMP certified operations. Prior disclosure of 758% YoY increase in export sales supports the narrative of international growth. Call-heavy options positioning aligns with bullish sentiment.
Insiders are selling and the selling amount increased ~456% over the last month (near-term confidence negative). Technical momentum is still weakening (MACD negative and expanding). Latest quarter shows top-line decline YoY (revenue down ~19.9%), which can cap upside until growth re-accelerates.
2025/Q3: Revenue fell to $66.74M (-19.94% YoY), indicating contraction in the top line. Net income was $10.22M but declined sharply YoY (reported -1345.98%), and EPS was $0.08 (reported -900% YoY), implying earnings were much less favorable versus the prior-year base. The standout positive is profitability quality: gross margin rose to 47.85% (+153.98% YoY), suggesting meaningful mix/efficiency improvement even while revenue declined. Overall: margin trend improved, growth trend weakened.
Most recent update (2025-11-10): Alliance Global Partners reiterated Buy and raised the price target to $5 from $3.50 after an “exceptional” quarter, citing sales/EBITDA far above estimates and a constructive outlook; they also raised forward sales models. Wall Street pros: improving margin profile and international/export expansion narrative. Cons: uneven revenue trajectory and heavy insider selling can undermine confidence in the near-term upside path. Politician/congress activity: no recent congress trading data available.
